Thera-SAbDab

ANIFROLUMAB

>   Structural Summary
TherapeuticAnifrolumab
TargetIFNAR1
Heavy ChainEVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK
100% seqID Fv Structure4qxg [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedMedarex, Medical University of Vienna, MedImmune
Conditions ApprovedSystemic lupus erythematosus
Conditions ActiveLupus nephritis
Conditions DiscontinuedRheumatoid arthritis, Scleroderma
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy